What is StemBioSys?
StemBioSys, Inc., a San Antonio-based biomedical firm, specializes in the manufacturing and development of advanced cell culture technologies. Leveraging patented and proprietary platforms licensed from the University of Texas System, the company focuses on creating clinically applicable cell therapies. StemBioSys markets its cutting-edge products under the CELLvo brand name, catering to the global research community and driving innovation in regenerative medicine.
How much funding has StemBioSys raised?
StemBioSys has raised a total of $13.2M across 4 funding rounds:
Unspecified
$2.4M
Series A
$8M
Private Equity
$2.7M
Debt
$150K
Unspecified (2013): $2.4M, investors not publicly disclosed
Series A (2015): $8M, investors not publicly disclosed
Private Equity (2016): $2.7M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
What's next for StemBioSys?
The recent major strategic investment signals a new phase of growth and expansion for StemBioSys. This capital infusion is anticipated to bolster research and development efforts, potentially leading to the scaling of its manufacturing capabilities and broader market penetration. The company's focus on regenerative medicine positions it to capitalize on the growing demand for advanced therapeutic solutions, with future developments likely centered on clinical translation and strategic partnerships within the biotech sector.
See full StemBioSys company page
